ClinicalTrials.gg
CompletedNCT04819776Updated Apr 18, 2024Results posted

Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder

A Phase 3 interventional study of Iloperidone and Iloperidone Placebo in Bipolar I Disorder, sponsored by Vanda Pharmaceuticals. Completed at 27 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-04-18.

Sponsored by Vanda Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
417
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The aim of this study is to investigate the efficacy, safety, and tolerability of iloperidone compared with placebo in treating acute manic or mixed episodes associated with Bipolar I Disorder.

02

Conditions studied

  • Bipolar I Disorder
03

In context

Lead sponsor

Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients 18 to 65 years of age (inclusive)
  • Diagnosed with bipolar I disorder, manic or mixed-type, per criteria
  • Voluntary hospitalization for current manic episode

Exclusion criteria

Exclusion Criteria:

  • Patients with a diagnosis of a psychiatric disorder other than bipolar I disorder that was the primary focus of treatment within the previous six months
  • Patients who are experiencing a first manic episode or meeting criteria for rapid cycling
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
417 participants (actual)

Study arms

  • Experimental
    Iloperidone

    Drug: Iloperidone

  • Placebo comparator
    Placebo

    Drug: Iloperidone Placebo

Interventions

  • Oral iloperidone

    Also known as: FANAPT®, VYV-683

  • DrugIloperidone Placebo

    Oral placebo

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 4 in Young Mania Rating Scale (YMRS) Total Score

    The Young Mania Rating Scale (YMRS) is an 11-item scale. Individual item scores are summed for a total possible score of 0 (best) to 60 (worst).

    Time frame: Week 4

07

Results

Posted Apr 16, 2024

Participant flow

Participant flow — Overall Study
MilestoneIloperidonePlacebo
Started206208
Completed139153
Not completed6755

Outcome measures

PrimaryChange From Baseline to Week 4 in Young Mania Rating Scale (YMRS) Total Score

The Young Mania Rating Scale (YMRS) is an 11-item scale. Individual item scores are summed for a total possible score of 0 (best) to 60 (worst).

Time frame:
Week 4
Reported as:
Mean · Change from Baseline in YMRS Total Score
Change From Baseline to Week 4 in Young Mania Rating Scale (YMRS) Total Score
Change from Baseline in YMRS Total ScoreIloperidonePlacebo
Change From Baseline to Week 4 in Young Mania Rating Scale (YMRS) Total Score-14.0 ± 0.64-10.0 ± 0.63

Adverse events

Collected over AE data was collected during the 28 day study period plus a 7 day follow up period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Iloperidone0/206 (0%)4/206 (1.9%)88/206 (42.7%)
Placebo0/208 (0%)1/208 (0.5%)25/208 (12%)
Most frequent serious events
Most frequent serious events
EventIloperidonePlacebo
Gastrointestinal haemorrhageGastrointestinal disorders1/2060/208
SedationNervous system disorders1/2060/208
Spontaneous penile erectionReproductive system and breast disorders1/2060/208
Respiratory distressRespiratory, thoracic and mediastinal disorders1/2060/208
Bipolar disorder (depression)Psychiatric disorders0/2061/208
Most frequent other events
Most frequent other events
EventIloperidonePlacebo
TachycardiaCardiac disorders36/20611/208
DizzinessNervous system disorders23/2062/208
Dry mouthGastrointestinal disorders19/2064/208
Alanine aminotransferase increasedInvestigations15/2061/208
Nasal congestionRespiratory, thoracic and mediastinal disorders13/2063/208
Weight increasedInvestigations12/2063/208
SomnolenceNervous system disorders11/2064/208

Baseline characteristics

Age, Continuous
Age, Continuous(years)IloperidonePlaceboTotal
Mean42.9 ± 12.7643.9 ± 12.5543.4 ± 12.65
Sex: Female, Male
Sex: Female, Male(Participants)IloperidonePlaceboTotal
Female9096186
Male116112228
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)IloperidonePlaceboTotal
White133132265
Black or African American6255117
Asian033
Native Hawaiian or Other Pacific Islander101
American Indian or Alaska Native134
Other91524
08

Study locations

27 sites
  • Vanda Investigational Site
    Little Rock, Arkansas 72211, United States
  • Vanda Investigational Site
    Rogers, Arkansas 72758, United States
  • Vanda Investigational Site
    Cerritos, California 90703, United States
  • Vanda Investigational Site
    Culver City, California 90230, United States
  • Vanda Investigational Site
    Long Beach, California 90806, United States
  • Vanda Investigational Site
    Orange, California 92868, United States
  • Vanda Investigational Site
    Torrance, California 90502, United States
  • Vanda Investigational Site
    Miami Lakes, Florida 33016, United States
  • Vanda Investigational Site
    Oakland Park, Florida 33334, United States
  • Vanda Investigational Site
    Atlanta, Georgia 30331, United States
  • Vanda Investigational Site
    Decatur, Georgia 30030, United States
  • Vanda Investigational Site
    Gaithersburg, Maryland 20877, United States
  • Vanda Investigational Site
    Flowood, Mississippi 39232, United States
  • Vanda Investigational Site
    Las Vegas, Nevada 89102, United States
  • Vanda Investigational Site
    Marlton, New Jersey 08053, United States
  • Vanda Investigational Site
    Dayton, Ohio 45417, United States
  • Vanda Investigational Site
    North Canton, Ohio 44720, United States
  • Vanda Investigational Site
    Austin, Texas 78754, United States
  • Vanda Investigational Site
    DeSoto, Texas 75115, United States
  • Vanda Investigational Site
    Richardson, Texas 75080, United States
  • Vanda Investigational Site
    Novi Iskar, Sofia City 1282, Bulgaria
  • Vanda Investigational Site
    Tserova Koria, Veliko Tarnovo 5047, Bulgaria
  • Vanda Investigational Site
    Kardzhali, 6600, Bulgaria
  • Vanda Investigational Site
    Lovech, 5500, Bulgaria
  • Vanda Investigational Site
    Veliko Tarnovo, 5000, Bulgaria
  • Vanda Investigational Site
    Vratsa, 3001, Bulgaria
  • Vanda Investigational Site
    Tuszyn, 95-080, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Sep 2022, 17 months.

Results were first posted in Apr 2024, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2021
First posted
Mar 29, 2021
StartActual
Mar 22, 2021
Primary completionActual
Sep 7, 2022
CompletionActual
Aug 16, 2023
Results first posted
Apr 16, 2024
Last update
Apr 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04819776
Responsible party
Sponsor
First posted
Mar 29, 2021
Start date
Mar 22, 2021
Primary completion
Sep 7, 2022
Completion
Aug 16, 2023
Results posted
Apr 16, 2024
Last update
Apr 18, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iloperidone

Start the discussion